Following ASCO GI 2024, Pamela L. Kunz, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from the CheckMate 8HW study investigating nivolumab plus ipilimumab in MSI-high/mismatch repair deficient metastatic colorectal cancer.
Pamela L. Kunz, MD, and the Oncology Brothers provide insights on the EMERALD-1 trial looking at durvalumab and bevacizumab plus TACE in patients with unresectable, embolization-eligible hepatocellular carcinoma.
Clinical insights on the recent data from the NETTER-2 trial looking at Lu-177 Dotatate in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Medical oncologists offer comprehensive insights on the role of circulating tumor DNA in the treatment of patients with colorectal cancer.
Following their review of recent data from the 2024 ASCO GI Cancers Symposium, the Oncology Brothers discuss their key takeaways.